Skip to main content
Erschienen in: Journal of General Internal Medicine 11/2023

30.05.2023 | Original Research

Rates and Correlates of Uptake of Continuous Glucose Monitors Among Adults with Type 2 Diabetes in Primary Care and Endocrinology Settings

verfasst von: Lindsay S. Mayberry, PhD, MS, Charmin Guy, MS, Chase D. Hendrickson, MD, MPH, Allison B. McCoy, PhD, ACHIP, FAMIA, Tom Elasy, MD, MPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinical trials indicate continuous glucose monitor (CGM) use may benefit adults with type 2 diabetes, but CGM rates and correlates in real-world care settings are unknown.

Objective

We sought to ascertain prevalence and correlates of CGM use and to examine rates of new CGM prescriptions across clinic types and medication regimens.

Design

Retrospective cohort using electronic health records in a large academic medical center in the Southeastern US.

Participants

Adults with type 2 diabetes and a primary care or endocrinology visit during 2021.

Main Measures

Age, gender, race, ethnicity, insurance, clinic type, insulin regimen, hemoglobin A1c values, CGM prescriptions, and prescribing clinic type.

Key Results

Among 30,585 adults with type 2 diabetes, 13% had used a CGM. CGM users were younger and more had private health insurance (p < .05) as compared to non-users; 72% of CGM users had an intensive insulin regimen, but 12% were not taking insulin. CGM users had higher hemoglobin A1c values (both most recent and most proximal to the first CGM prescription) than non-users. CGM users were more likely to receive endocrinology care than non-users, but 23% had only primary care visits in 2021. For each month in 2021, a mean of 90.5 (SD 12.5) people started using CGM. From 2020 to 2021, monthly rates of CGM prescriptions to new users grew 36% overall, but 125% in primary care. Most starting CGM in endocrinology had an intensive insulin regimen (82% vs. 49% starting in primary care), whereas 28% starting CGM in primary care were not using insulin (vs. 5% in endocrinology).

Conclusion

CGM uptake for type 2 diabetes is increasing rapidly, with most growth in primary care. These trends present opportunities for healthcare system adaptations to support CGM use and related workflows in primary care to support growth in uptake.
Literatur
5.
6.
Zurück zum Zitat Perrin N, Davies M, Robertson N, Snoek F, Khunti K. The prevalence of diabetes‐specific emotional distress in people with type 2 diabetes: a systematic review and meta‐analysis. Diabet Med. 2017;34(11):1508-20.CrossRefPubMed Perrin N, Davies M, Robertson N, Snoek F, Khunti K. The prevalence of diabetes‐specific emotional distress in people with type 2 diabetes: a systematic review and meta‐analysis. Diabet Med. 2017;34(11):1508-20.CrossRefPubMed
7.
Zurück zum Zitat Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365-74. https://doi.org/10.7326/M16-2855. PubMed PMID: 28828487.CrossRefPubMed Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365-74. https://​doi.​org/​10.​7326/​M16-2855. PubMed PMID: 28828487.CrossRefPubMed
8.
Zurück zum Zitat Kompala T, Neinstein A. A new era: increasing continuous glucose monitoring use in type 2 diabetes. Am J Manag Care. 2019;25(4 Spec No.):Sp123-sp6. PubMed PMID: 30933461.PubMed Kompala T, Neinstein A. A new era: increasing continuous glucose monitoring use in type 2 diabetes. Am J Manag Care. 2019;25(4 Spec No.):Sp123-sp6. PubMed PMID: 30933461.PubMed
10.
Zurück zum Zitat Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology—continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922-37.CrossRefPubMed Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology—continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922-37.CrossRefPubMed
11.
Zurück zum Zitat American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S71-S80.CrossRef American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S71-S80.CrossRef
12.
Zurück zum Zitat DeSalvo DJ, Noor N, Xie C, Corathers SD, Majidi S, McDonough RJ, et al. Patient demographics and clinical outcomes among type 1 diabetes patients using continuous glucose monitors: data from T1D Exchange Real-World Observational Study. J Diabet Sci Technol. 2021;0(0):19322968211049783. https://doi.org/10.1177/19322968211049783. PubMed PMID: 34632823.CrossRef DeSalvo DJ, Noor N, Xie C, Corathers SD, Majidi S, McDonough RJ, et al. Patient demographics and clinical outcomes among type 1 diabetes patients using continuous glucose monitors: data from T1D Exchange Real-World Observational Study. J Diabet Sci Technol. 2021;0(0):19322968211049783. https://​doi.​org/​10.​1177/​1932296821104978​3. PubMed PMID: 34632823.CrossRef
16.
Zurück zum Zitat Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA. 2021;325(22):2273-84. https://doi.org/10.1001/jama.2021.6530. PubMed PMID: 34077502; PubMed Central PMCID: PMC8173463.CrossRefPubMed Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA. 2021;325(22):2273-84. https://​doi.​org/​10.​1001/​jama.​2021.​6530. PubMed PMID: 34077502; PubMed Central PMCID: PMC8173463.CrossRefPubMed
17.
Zurück zum Zitat Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262-72. https://doi.org/10.1001/jama.2021.7444. PubMed PMID: 34077499; PubMed Central PMCID: PMC8173473.CrossRefPubMed Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262-72. https://​doi.​org/​10.​1001/​jama.​2021.​7444. PubMed PMID: 34077499; PubMed Central PMCID: PMC8173473.CrossRefPubMed
23.
Zurück zum Zitat Oser T, Hall T, Warman MK, Filippi MK, Manning B, Callen E, et al. 651-P: Continuous glucose monitoring in primary care: explaining characteristics associated with CGM prescription. Diabetes. 2022;71(Supplement_1). https://doi.org/10.2337/db22-651-P. Oser T, Hall T, Warman MK, Filippi MK, Manning B, Callen E, et al. 651-P: Continuous glucose monitoring in primary care: explaining characteristics associated with CGM prescription. Diabetes. 2022;71(Supplement_1). https://​doi.​org/​10.​2337/​db22-651-P.
24.
Zurück zum Zitat Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, et al. Individualized glycemic control for U.S. adults with type 2 diabetes: a cost-effectiveness analysis. Ann Intern Med. 2018;168(3):170-8. https://doi.org/10.7326/M17-0537. PubMed PMID: 29230472; PubMed Central PMCID: PMC5989575.CrossRefPubMed Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, et al. Individualized glycemic control for U.S. adults with type 2 diabetes: a cost-effectiveness analysis. Ann Intern Med. 2018;168(3):170-8. https://​doi.​org/​10.​7326/​M17-0537. PubMed PMID: 29230472; PubMed Central PMCID: PMC5989575.CrossRefPubMed
27.
Zurück zum Zitat Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabet Technol Ther. 2019;21(2):66-72.CrossRef Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabet Technol Ther. 2019;21(2):66-72.CrossRef
28.
Zurück zum Zitat Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41(11):2265-74.CrossRefPubMed Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41(11):2265-74.CrossRefPubMed
Metadaten
Titel
Rates and Correlates of Uptake of Continuous Glucose Monitors Among Adults with Type 2 Diabetes in Primary Care and Endocrinology Settings
verfasst von
Lindsay S. Mayberry, PhD, MS
Charmin Guy, MS
Chase D. Hendrickson, MD, MPH
Allison B. McCoy, PhD, ACHIP, FAMIA
Tom Elasy, MD, MPH
Publikationsdatum
30.05.2023
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 11/2023
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-023-08222-3

Weitere Artikel der Ausgabe 11/2023

Journal of General Internal Medicine 11/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.